HETEROCYCLES, Vol. 71, No. 2, 2007, pp. 331 – 341. © The Japan Institute of Heterocyclic Chemistry Received, 6th November, 2006, Accepted, 12th December, 2006, Published Online, 15th December, 2006. COM-06-10934

STRUCTURES OF NEW CUCURBITANE-TYPE TRITERPENES AND GLYCOSIDES, KARAVILAGENINS D AND E, AND KARAVILOSIDES VI, VII, VIII, IX, X, AND XI, FROM THE FRUIT OF *MOMORDICA CHARANTIA*

Hisashi Matsuda, Seikou Nakamura, Toshiyuki Murakami, and Masayuki Yoshikawa*

Kyoto Pharmaceutical University, Misasagi, Yamashina-ku, Kyoto 607-8412, Japan, e-mail address: myoshika@mb.kyoto-phu.ac.jp

Abstract — Two new cucurbitane-type triterpenes, karavilagenins D and E, and six new cucurbitane-type triterpene glycosides, karavilosides VI, VII, VIII, IX, X, and XI, were isolated from the fruit of *Momordica charantia* L. (Cucurbitaceae) cultivated in Sri Lanka. Their structures were elucidated on the basis of chemical and physicochemical evidence.

The Cucurbitaceae plant *Momordica* (M.) charantia L. has been widely cultivated in India and tropical Asian countries. The fruit of this plant has been used not only as a vegetable but also as a traditional medicine for rheumatism, gout, diabetes, and diseases of liver in Sri Lanka, India, China, and Southeast Asian countries. The alcoholic extract from the fruit of M. charantia originated in Sri Lanka was reported to inhibit the increase of serum glucose levels in glucose-loaded rats.¹ In addition, many cucurbitane-type triterpene glycosides were isolated from the fruit of this plant originated in Japan and Taiwan.²⁻⁹ In previous studies, we have reported the isolation and structure elucidation of eight cucurbitane-type triterpene glycosides, goyaglycosides a, b, c, d, e, f, g, and h, and three oleanane-type triterpene glycosides, goyasaponins I, II, and III, from the fresh fruit of Japanese M. charantia.¹⁰ Furthermore, three new cucurbitane-type triterpenes, karavilagenins A, B, and C, and five new cucurbitane-type triterpene glycosides, karavilosides I, II, III, IV, and V, were isolated from the dried fruit of M. charantia cultivated in Sri Lanka.¹¹ As a continuing study on Sri Lanka M. charantia, we have isolated two new cucurbitanetype triterpenes, karavilagenins D (1) and F (2), and five new cucurbitane-type triterpene glycosides, karavilosides VI (3), VII (4), VIII (5), IX (6), X (7), and XI (8). This paper deals with the isolation and structure elucidation of new cucurbitane-type triterpenes and glycosides from the fruit of *M. charantia*. The saponin fraction was obtained from the methanolic extract from the fruit of *M. charantia* cultivated in Nuwara Eliya, Sri Lanka, which was described previously.¹¹ The saponin fraction was further separated by HPLC to give 1 (0.0010%), 2 (0.0006%), 3 (0.0017%), 4 (0.0003%), 5 (0.0020%), 6 (0.0042%), 7 (0.0006%), and **8** (0.0006%).



Structures of Karavilagenins D (1) and E (2) and Karavilosides VI-XI (3-8)

Karavilagenin D (1) was obtained as a white powder with negative optical rotation ($[\alpha]_{D}^{26}$ –94.4°). The IR spectrum of **1** showed absorption bands at 3475 and 1765 cm⁻¹ suggestive of hydroxy and carbonyl functions. In the positive-ion FAB-MS of 1, a quasimolecular ion peak was observed at m/z 493 (M+Na)⁺ and the molecular formula C₃₀H₄₆O₄ was determined by high-resolution MS measurement. The ¹H-NMR (pyridine- d_5) and ¹³C-NMR (Table 1) spectra of **1**, which were assigned by various NMR experiments,¹² showed signals due to seven methyls [$\delta 0.86, 0.93, 0.95, 1.27$ (3H each, all s, 29, 18, 28, 30-H₃), 0.89 (3H, d-like, $21-H_3$, 1.31 (6H, s, 26, $27-H_3$)], a methine bearing an oxygen function [3.42 (1H, br s, 3-H)], and four olefinic protons [5.60 (2H, m, 23, 24-H), 5.73 (1H, dd, J=3.3, 9.6 Hz, 7-H), 6.21 (1H, d, J=9.6 Hz, 6-H)]. The plane structure of 1 was determined by a detailed heteronuclear multiple bond correlation (HMBC) experiment. Namely, long-range correlations were observed between the following protons and carbons: 3-H and 5-C; 7-H and 9-C; 11-H₂ and 19-C; 18-H₃ and 12, 13, 14, 17-C; 21-H₃ and 17, 20, 22-C; 23-H and 22, 24, 25-C; 24-H and 22, 23, 25, 26, 27-C; 26, 27-H₃ and 24, 25-C; 28, 29-H₃ and 3, 4, 5-C; 30-H₃ and 8, 13, 14, 15-C (Figure 1). The stereostructure of **1** was characterized by a nuclear Overhauser enhancement spectroscopy (NOESY) experiment, which showed NOE correlations between the following proton pairs: 8-H and 18-H₃; 28-H₃ and 3-H, 10-H; 30-H₃ and 10-H, 17-H (Figure 1). These findings and comparisons of ¹H-NMR and ¹³C-NMR spectra of **1** with those of known cucurbitane-type triterpenes^{10,11} led us to formulate the structure of karavilagenin D as 5β , 19-epoxycucurbita-6, 23-dien-19-on- 3β , 25-diol (1).

Karavilagenin E (2) was obtained as a white powder with negative optical rotation ($[\alpha]_D^{26}$ –41.0°). The IR spectrum of 2 showed absorption bands at 3475, 1055 cm⁻¹ suggestive of hydroxy and ether functions. In

	1	2	3	4	5	6	7	8
C-1	18.4	17.6	19.8	18.9	17.8	18.7	18.9	19.0
C-2	26.5	27.3	26.5	27.9	27.8	27.4	27.5	27.6
C-3	75.2	76.2	84.3	85.3	76.1	85.2	85.1	85.1
C-4	37.0	37.2	38.5	39.1	37.4	38.9	39.0	39.0
C-5	85.3	85.5	85.3	85.9	87.5	85.9	86.1	86.0
C-6	131.1	131.8	132.5	134.2	132.4	133.9	134.1	134.1
C-7	133.3	131.5	133.0	130.0	131.2	129.9	130.1	130.0
C-8	44.4	52.0	45.0	52.3	52.1	52.2	52.3	52.4
C-9	51.0	45.5	50.8	45.4	45.6	45.3	45.3	45.4
C-10	39.9	38.8	40.8	40.2	39.2	40.0	40.2	40.2
C-11	21.6	23.6	21.9	23.9	23.7	23.7	23.8	23.9
C-12	29.7	30.9	30.1	31.3	31.1	31.1	31.2	31.3
C-13	45.0	45.4	45.4	45.7	45.6	45.6	45.7	45.7
C-14	47.7	48.6	48.0	49.0	48.4	48.4	48.6	49.0
C-15	33.2	33.1	33.5	33.4	33.5	33.5	33.7	33.4
C-16	27.4	28.2	27.7	28.5	27.9	27.9	28.1	28.5
C-17	50.1	50.9	50.5	51.4	46.5	46.5	46.7	51.7
C-18	14.5	14.9	14.7	15.0	14.4	14.4	14.5	15.0
C-19	181.4	79.9	182.1	80.2	79.8	79.9	80.2	80.2
C-20	36.1	32.6	36.4	32.8	40.6	40.6	40.8	32.7
C-21	18.5	18.6	18.8	19.1	14.6	14.6	14.8	19.0
C-22	39.0	44.4	39.7	43.4	76.5	76.5	76.7	43.3
C-23	125.0	65.9	128.3	75.9	80.9	80.9	81.1	67.8
C-24	139.6	129.0	137.8	128.0	124.6	124.6	124.1	79.9
C-25	70.7	133.9	74.9	134.5	135.3	135.2	135.4	73.6
C-26	29.9	18.1	26.1	25.8	26.0	26.0	26.2	27.9
C-27	29.8	25.7	26.5	18.2	18.5	18.5	18.6	27.0
C-28	19.2	20.5	20.9	21.1	20.8	20.8	21.0	21.1
C-29	23.5	24.5	24.0	25.7	24.5	25.5	25.6	25.6
C-30	20.3	20.0	19.4	20.3	20.1	20.2	20.2	20.2
23-OMe				55.6				
25-OMe			50.2					
C-1'			107.6	106.6	103.4	106.6	103.9	103.7
C-2'			74.5	75.0	72.9	75.5	73.0	73.1
C-3'			78.7	78.4	72.8	78.1	72.4	72.4
C-4'			71.8	72.0	68.9	71.8	69.3	69.4
C-5'			78.4	78.4	75.7	78.0	76.1	76.1
C-6'			63.2	63.2	62.9	62.9	63.4	63.4
C-1"						103.3	103.6	
C-2"						72.9	73.1	
C-3"						72.8	73.0	
C-4"						68.9	69.1	
C-5"						75.7	75.9	
C-6"						62.9	63.1	

Table 1. 13 C-NMR Data (125 MHz, pyridine- d_5) for Karavilagenins D (1) and E (2) and
Karavilosides VI (3), VII (4), VIII (5), IX (6), X (7), and XI (8).

the positive-ion FAB-MS of **2**, a quasimolecular ion peak was observed at m/z 457 (M+H)⁺ and the molecular formula $C_{30}H_{49}O_3$ was determined by high-resolution MS measurement. The ¹H-NMR and ¹³C-NMR spectra of **2**,¹² showed signals due to seven methyls [δ 0.86, 1.20, 1.69, 1.71 (3H each, all s, 30, 28, 27, 26-H₃), 0.90 (6H, s, 18, 29-H₃), 0.98 (3H, d, *J*=6.3 Hz, 21-H₃)], two methines bearing an oxygen function [3.41 (1H, dd-like, 3-H), 4.46 (1H, ddd, *J*=3.0, 8.3, 11.8 Hz, 23-H)], a methylene bearing an oxygen function [3.51, 3.67 (1H each, both d, *J*=8.6 Hz, 19-H₂)], and three olefinic protons [5.20 (1H, d,



Figure 1 Selected HMBC and NOE Correlations

J=8.3 Hz, 24-H), 5.64 (1H, dd, J=3.6, 9.9 Hz, 7-H), 6.04 (1H, d, J=9.9 Hz, 6-H)]. The proton and carbon signals due to the side chain part (20-C ~ 27-C) in the ¹H- and ¹³C-NMR spectra of **2** were superimposable on those of karavilagenin C (**9**),¹¹ while the signals due to the tetracyclic part were similar to those of 5β ,19-epoxycucurbita-6,23-diene- 3β ,25-diol.¹⁰ The plane structure of **2** was determined by a detailed HMBC experiment. Namely, long-range correlations were observed between the following protons and carbons: 3-H and 5-C; 7-H and 9-C; 18-H₃ and 12, 13, 14, 17-C; 19-H₂ and 5, 8, 9-C; 21-H₃ and 17, 20, 22-C; 24-H and 22, 25, 26, 27-C; 26, 27-H₃ and 24, 25-C; 28, 29-H₃ and 3, 4, 5-C; 30-H₃ and 8, 13, 14, 15-C (Figure 1). The stereostructure of **2**, except for the 23-position, was characterized by a NOESY experiment, which showed NOE correlations between the following proton pairs: 8-H and 18-H₃, 19-H₂; 28-H₃ and 3-H, 10-H; 30-H₃ and 10-H, 17-H (Figure 1). Consequently, the structure of karavilagenin E was determined to be 5β ,19-epoxycucurbita-6,24-dien- 3β ,23 ξ -diol (**2**).

Karaviloside VI (**3**) was obtained as a white powder with negative optical rotation ($[\alpha]_D^{28}$ –80.0°). The IR spectrum of **3** showed absorption bands at 3432, 1750, 1078, and 1040 cm⁻¹ suggestive of carbonyl and glycosidic functions. In the negative- and positive-ion FAB-MS of **3**, quasimolecular ion peaks were observed at m/z 645 (M–H)⁻, m/z 669 (M+Na)⁺, and m/z 691 (M+2Na–H)+ and the molecular formula C₃₇H₅₈O₉ was determined by high-resolution MS measurement. Acid hydrolysis of **3** with 5% aqueous sulfuric acid (H₂SO₄)–1,4-dioxane (1 : 1, v/v) furnished D-glucose, which was identified by GLC analysis of the thiazolidine derivative.¹³ The ¹H-NMR and ¹³C-NMR spectra of **3**,¹² showed signals due to a β -D-glucopyranosyl moiety [δ 4.83 (d, *J*=7.9 Hz, 1'-H)] and an aglycone moiety [δ 0.83, 0.89, 0.94, 1.58 (all s,

30, 18, 29, 28-H₃), 0.95 (d-like, 21-H₃), 1.33 (s, 26, 27-H₃), 3.22 (s, 25-OCH₃), 3.67 (br s, 3-H), 5.57 (d, J=15.9 Hz, 24-H), 5.65 (m, 6, 23-H), 6.33 (dd, J=2.1, 9.5 Hz, 7-H)]. The plane structure of the aglycone moiety in **3** was determined by a detailed HMBC experiment, in which long-range correlations were observed between the following protons and carbons: 3-H and 5-C; 7-H and 9-C; 11-H₂ and 19-C; 18-H₃ and 12, 13, 14, 17-C; 21-H₃ and 17, 20, 22-C; 23-H and 22, 25-C; 24-H and 22, 25, 26, 27-C; 26, 27-H₃ and 24, 25-C; 28, 29-H₃ and 3, 4, 5-C; 30-H₃ and 8, 13, 14, 15-C; 25-OCH₃ and 25-C; 1'-H and 3-C (Figure 1). The stereostructure of the aglycone moiety was characterized by a NOESY experiment, which showed NOE correlations between the following proton pairs: 8-H and 18-H₃; 28-H₃ and 3-H, 10-H; 30-H₃ and 10-H, 17-H (Figure 1). These findings and comparisons of ¹H-NMR and ¹³C-NMR spectra of **3** with those of known cucurbitane-type triterpene glycosides (goyaglycosides, momordicosides, karavilosides I-V)^{10,11} led us to formulate the structure of kalaviloside VI as 25-methoxy-5 β ,19-epoxycucurbita-6,23-dien-19-on-3 β -ol 3-*O*- β -D-glucopyranoside (**3**).

Treatment of karavilagenin C (9), which was previously isolated from the fruits of Sri Lanka M. *charantia*,¹¹ with MeOH yielded karavilagenin A (10) (Scheme 1). On the basis of this finding, karaviloside VI (3) having the 25-methoxy group was presumed to be secondly formed from compounds having the 23-hydroxy group during the extraction or isolation procedure.



Karaviloside VII (**4**), which was obtained as a white powder with negative optical rotation $([\alpha]_D^{27} - 36.3^\circ)$, showed absorption bands at 3453, 1084, and 1034 cm⁻¹ suggestive of a glycosidic function in the IR spectrum. The molecular formula C₃₇H₆₀O₈ of **4** was determined from the positive-ion FAB-MS [*m*/z 633 (M+H)⁺] and by high-resolution MS measurement. Acid hydrolysis of **4** with 5% aqueous H₂SO₄–1,4-dioxane (1 : 1, v/v) furnished D-glucose, which was identified by GLC analysis of the thiazolidine derivative.¹³ The ¹H-NMR and ¹³C-NMR spectra of **4**,¹² showed signals due to a β -D-glucopyranosyl moiety [δ 4.90 (1H, d, *J*=7.6 Hz, 1'-H)] and an aglycone moiety [δ 0.90, 0.80, 0.93, 1.52, 1.71, 1.75 (3H each, all s, 30, 18, 29, 28, 26, 27-H₃), 1.06 (3H, d, *J*=6.4 Hz, 21-H₃), 3.30 (3H, s, 23-OMe), 3.59, 3.73 (1H each, both d, *J*=8.0 Hz, 19-H₂), 3.69 (1H, br s, 3-H), 3.96 (1H, m, 23-H), 5.23 (1H, d-like, 24-H), 5.57 (1H, dd, *J*=4.0, 9.8 Hz, 7-H), 6.21 (1H, d-like, 6-H)]. The plane structure of the aglycone moiety in **4** was determined by a detailed HMBC experiment, in which long-range correlations were observed between the following protons and carbons: 3-H and 5-C; 7-H and 9-C; 18-H₃ and 12, 13, 14, 17-C; 19-H₂ and 5, 8, 9-C; 21-H₃ and 17, 20, 22-C; 24-H and 22, 25, 26, 27-C; 26, 27-H₃ and 24, 25-C; 28, 29-H₃ and 3, 4, 5-C; 30-H₃ and 8, 13, 14, 15-C; 23-OCH₃ and 23-C; 1'-H and 3-C (Figure 1). The stereostructure of the aglycone moiety, except for the 23-position, was characterized by a NOESY experiment, which showed

NOE correlations between the following proton pairs: 8-H and 18-H₃, 19-H₂; 28-H₃ and 3-H, 10-H; 30-H₃ and 10-H, 17-H (Figure 1). Consequently, the structure of karaviloside VII was determined to be 23ξ -methoxy- 5β ,19-epoxycucurbita-6,24-dien- 3β -ol 3-O- β -D-glucopyranoside (**4**).

Karaviloside VIII (5), which was obtained as a white powder with negative optical rotation ($\left[\alpha\right]_{D}^{28}$ -47.4°), showed absorption bands at 3520, 1084, and 1034 cm⁻¹ in the IR spectrum. The negative- and positive-ion FAB-MS of 5 showed quasimolecular ion peaks at m/z 633 (M–H)⁻, m/z 635 (M+H)⁺, and m/z 657 $(M+Na)^+$ and the molecular formula $C_{36}H_{58}O_9$ was determined by high-resolution MS measurement. Acid hydrolysis of **5** with 5% aqueous H_2SO_4 -1,4-dioxane (1 : 1, v/v) furnished D-allose, which was identified by GLC analysis of the thiazolidine derivative.^{10,11,13} The ¹H-NMR and ¹³C-NMR spectra of **5**¹² showed signals due to a β -D-allopyranosyl moiety [δ 5.53 (1H, d, J=7.9 Hz, 1'-H)] and an aglycone moiety $[\delta 0.77, 0.87, 0.89, 1.35, 1.64, 1.85 (3H each, all s, 18, 30, 29, 28, 26, 27-H_3), 1.16 (3H, d, J=6.9 Hz, 21-$ H₃), 3.51 (1H, br s, 3-H), 3.55, 3.74 (1H each, both d, J=8.3 Hz, 19-H₂), 4.02 (1H, dd, J=2.2, 7.9 Hz, 22-H), 4.64 (1H, t-like, 23-H), 5.51 (1H, m, 24-H), 5.62 (1H, dd, J=3.6, 9.9 Hz, 7-H), 6.14 (1H, d, J=9.9 Hz, 6-H)]. The ¹H- and ¹³H-NMR signals due to the side chain part (20-C \sim 27-C) of **5** were superimposable on those of karaviloside V,¹¹ whereas the signals due to the tetracyclic part very resembled those of karavilagenin E (2). The plane structure of aglycone moiety in 5 was determined by a detailed HMBC experiment. Namely, long-range correlations were observed between the following protons and carbons: 3-H and 5-C; 7-H and 9-C; 18-H₃ and 12, 13, 14, 17-C; 19-H₂ and 5, 8, 9-C; 21-H₃ and 17, 20, 22-C; 24-H and 22, 25, 26, 27-C; 26, 27-H₃ and 24, 25-C; 28, 29-H₃ and 3, 4, 5-C; 30-H₃ and 8, 13, 14, 15-C; 1'-H and 23-C (Figure 1). The stereostructure of the aglycone moiety, except for the side chain part, was characterized by a NOESY experiment, in which NOE correlations were observed between the following proton pairs: 8-H and 18-H₃, 19-H₂; 28-H₃ and 3-H, 10-H; 30-H₃ and 10-H, 17-H (Figure 1). Consequently, the structures of karaviloside VIII was determined to be 5β , 19-epoxycucurbita-6, 24-dien- 3β , 22 ξ , 23 ξ -triol 23-O- β -D-allopyranoside (5).

Karavilloside IX (6) and X (7) with negative optical rotation (6: $[\alpha]_D^{26} - 96.6^\circ$; 7: $[\alpha]_D^{28} - 80.7^\circ$) were found to have the same molecular formula, $C_{42}H_{68}O_{14}$, which was determined from the quasimolecular ion peaks in their negative-ion FAB-MS $[m/z 795 (M-H)^-, m/z 633 (M-C_6H_{11}O_5)^-]$ and positive-ion FAB-MS $[m/z 797 (M+H)^+$ and $m/z 819 (M+Na)^+]$ and by high-resolution MS measurement. The IR spectra of 6 and 7 showed absorption bands suggestive of a glycosidic function (6: 3453, 1082, and 1036 cm⁻¹; 7: 3432, 1084, 1034 cm⁻¹). Acid hydrolysis of 6 with 5% aqueous sulfuric acid $(H_2SO_4)-1,4$ -dioxane (1 : 1, v/v) furnished D-allose and D-glucose, which were identified by GLC analysis of their thiazolidine derivative.^{10,11,13} On the other hand, 7 furnished D-allose upon acid hydrolysis.^{10,11,13} The proton and carbon signals in the ¹H-NMR and ¹³C-NMR of 6 and 7 were superimposable on those of 5, except for the signals due to the 3-*O*-glycoside moiety. Namely, The ¹H-NMR and ¹³C-NMR spectra of 6 showed signals due to a β -D-glucopyranosyl moiety [δ 4.84 (1H, d, J=7.6 Hz, 1"-H)] and a β -D-allopyranosyl moiety [5.54 (d, J=7.9 Hz, 1'-H)] together with an aglycone moiety [δ 0.74, 0.88, 0.91, 1.48, 1.63, 1.83 (3H each, all s, 18, 30, 29, 28, 26, 27-H₃), 1.14 (3H, d, J=6.9 Hz, 21-H₃), 3.58, 3.73 (1H each, both d, J=7.9 Hz, 19-H₂), 3.65 (1H, br s, 3-H), 4.01 (1H, dd-like, 22-H), 4.68 (1H, t-like, 23-H), 5.54 (2H, m, 7, 24-H), 6.19 (1H, d, J=9.6 Hz, 6-H)]. The ¹H-NMR and ¹³C-NMR spectra of 7 showed signals due to a β -D-allopyranosyl moiety [δ 5.34 (1H, d, *J*=7.9 Hz, 1'-H) and 5.56 (d, *J*=7.9 Hz, 1"-H)] and an aglycone moiety [δ 0.75, 1.45, 1.63, 1.85 (3H each, all s, 18, 28, 26, 27-H₃), 0.89 (6H, s, 29, 30-H₃), 1.15 (3H, d, *J*=7.0 Hz, 21-H₃), 3.59, 3.76 (1H each, both d, *J*=8.3 Hz, 19-H₂), 3.62 (1H, br s, 3-H), 4.01 (1H, dd-like, 22-H), 4.63 (1H, t-like, 23-H), 5.52 (1H, d, *J*=10.2 Hz, 24-H), 5.77 (1H, dd, *J*=3.6, 9.8 Hz, 7-H), 6.18 (1H, d, *J*=9.8 Hz, 6-H)]. In the HMBC experiments on **6** and **7**, long-range correlations were observed between the following protons and carbons: 3-H and 5-C; 7-H and 9-C; 18-H₃ and 12, 13, 14, 17-C; 19-H₂ and 5, 8, 9-C; 21-H₃ and 17, 20, 22-C; 24-H and 22, 25, 26, 27-C; 26, 27-H₃ and 24, 25-C; 28, 29-H₃ and 3, 4, 5-C; 30-H₃ and 8, 13, 14, 15-C; 1'-H and 3-C; 1''-H and 23-C (Figure 1). Consequently, the structures of karavilosides IX and X were determined to be 23-*O*-β-D-allopyranosyl-5β,19-epoxycucurbita-6,24-dien-3β,22ξ,23ξ-triol 3-*O*-β-D-allopyranosyl-5β,19-epoxycucurbita-6,24-dien-3β,22ξ,23ξ-triol 3-*O*-β-D-allopyranosyl-5β,19-epoxycucurbita-6,24-dien-3β,22ξ

Karaviloside XI (8, $\left[\alpha\right]_{D}^{27}$ -49.5°) showed absorption bands at 3432, 1084, and 1032 cm⁻¹ in the IR spectrum. The molecular formula $C_{36}H_{60}O_{10}$ of 8 was determined from the negative- and positive-ion FAB-MS of 8 $[m/z \ 651 \ (M-H)^-, m/z \ 653 \ (M+H)^+, and m/z \ 675 \ (M+Na)^+]$ and by high-resolution MS measurement. Acid hydrolysis of 8 with 5% aqueous H_2SO_4 -1,4-dioxane (1 : 1, v/v) furnished D-allose, which was identified by GLC analysis of the thiazolidine derivative.^{10,11,13} The ¹H-NMR and ¹³C-NMR spectra of $\mathbf{8}^{12}$ showed signals due to a β -D-allopyranosyl moiety [δ 5.37 (1H, d, J=7.9 Hz, 1'-H)] and an aglycone moiety [δ 0.79, 0.88, 0.89, 1.46, 1.61, 1.63 (3H, s, 18, 30, 29, 28, 26, 27-H₃), 1.12 (3H, d, J=6.4 Hz, 21-H₃), 3.58, 3.76 (1H each, both d, J=7.9 Hz, 19-H₂), 3.52 (1H, d-like, 24-H), 3.65 (1H, br s, 3-H), 4.53 (1H, ddd-like, 23-H), 5.55 (1H, dd, J=3.9, 9.5 Hz, 7-H), 6.18 (1H, d, J=9.5 Hz, 6-H)]. The ¹H-NMR and ¹³C-NMR data due to the side chain part (20-C ~ 27-C) in the aglycon of 8 were similar to those of momordicoside C^3 , whereas the signals due to the tetracyclic part were superimposable on those of karaviloside X (7). In a HMBC experiment on 8, long-range correlations were observed between the following protons and carbons: 3-H and 5-C; 7-H and 9-C; 18-H₃ and 12, 13, 14, 17-C; 19-H₂ and 5, 8, 9-C; 21-H₃ and 17, 20, 22-C; 24-H and 22, 25, 26, 27-C; 26, 27-H₃ and 24, 25-C; 28, 29-H₃ and 3, 4, 5-C; 30-H₃ and 8, 13, 14, 15-C; 1'-H and 3-C (Figure 1). The NOESY experiment on 8 showed NOE correlations between the following proton pairs: 8-H and 18-H₃, 19-H₂; 28-H₃ and 3-H, 10-H; 30-H₃ and 10-H, 17-H (Figure 1). On the basis of this evidence, the structure of karaviloside XI was determined to be 5β , 19-epoxycucurbita-6-en- 3β , 23 ξ , 24 ξ , 25-tetraol 3-O- β -D-allopyranoside (8).

EXPERIMENTAL

The following instruments were used to obtain physical data: specific rotations, Horiba SEPA-300 digital polarimeter (l = 5 cm); IR spectra, Shimadzu FTIR-8100 spectrometer; FAB-MS and high-resolution MS, JEOL JMS-SX 102A mass spectrometer; ¹H-NMR spectra, JNM-LA500 (500 MHz) spectrometer; ¹³C-NMR spectra, JNM-LA500 (125 MHz) spectrometer with tetramethylsilane as an internal standard; and HPLC detector, Shimadzu RID-6A refractive index detector.

The following experimental conditions were used for chromatography: ordinary-phase silica gel column chromatography, Silica gel BW-200 (Fuji Silysia Chemical, Ltd., 150–350 mesh); reversed-phase silica

gel column chromatography, Chromatorex ODS DM1020T (Fuji Silysia Chemical, Ltd., 100–200 mesh); TLC, precoated TLC plates with Silica gel $60F_{254}$ (Merck, 0.25 mm) (ordinary phase) and Silica gel RP-18 F_{2548} (Merck, 0.25 mm) (reversed-phase); reversed-phase HPTLC, precoated TLC plates with Silica gel RP-18 WF₂₅₄₈ (Merck, 0.25 mm); and detection was achieved by spraying with 1% Ce(SO₄)₂–10% aqueous H₂SO₄ followed by heating.

Isolation of Karavilagenins D (1), and E (2), and Karavilosides VI (3), VII (4), VIII (5), IX (6), X (7), and XI (8)

Fractions 2 (37.9 g), 3 (27.6 g), and 7 (32.3 g) were obtained from the MeOH extract (4.9%) of the dried fruit of *M. charantia* L. (6.6 kg, cultivated in Nuwara Eliya, Sri Lanka) as reported previously.¹¹ Normalphase silica gel column chromatography [600 g, *n*-hexane–AcOEt (1 : 1 \rightarrow 1 : 5, v/v) \rightarrow MeOH] of fraction 2 (33 g) gave five fractions [Fr. 2-1 (9.9 g), 2-2 (2.7 g), 2-3 (2.3 g), 2-4 (1.9 g), 2-5 (14.6 g)]. Fraction 2-2 (2.7 g) was purified by reversed-phase silica gel column chromatography [80 g, MeOH-H₂O $(90:10, v/v) \rightarrow MeOH$ and HPLC [MeOH-H₂O (95:5, v/v)] to give karavilagenin E (2, 18 mg, 0.0006%). Fraction 2-4 (1.9 g) was purified by reversed-phase silica gel column chromatography [60 g, MeOH-H₂O (90 : 10, v/v) \rightarrow MeOH] and HPLC [MeOH-H₂O (90 : 10, v/v)] to give karavilagenin D (1, 29 mg, 0.0010%). Fraction 3 (27.6 g) was separated by normal-phase silica gel column chromatography [500 g, CHCl₃-MeOH (50 : 1 \rightarrow 50 : 3, v/v) \rightarrow MeOH] to give five fractions [Fr. 3-1 (7.6 g), 3-2 (4.4 g), 3-3 (4.0 g), 3-4 (7.2 g), 3-5 (3.6 g)]. Fraction 3-3 (4.0 g) was separated by reversed-phase silica gel column chromatography [120 g, MeOH–H₂O (80 : 20 \rightarrow 90 : 10, v/v) \rightarrow MeOH] to give four fractions [Fr. 3-3-1 (1.5 g), 3-3-2 (569 mg), 3-3-3 (1.2 g), 3-3-4 (509 mg)]. Fraction 3-3-2 (569 mg) was purified by HPLC [1] MeOH-H₂O (90 : 10, v/v); 2] CH₃CN-H₂O (80 : 20, v/v)] to give karaviloside VI (3, 56 mg, 0.0017%). Fraction 3-3-3 (1.2 g) was purified by HPLC [MeOH-H2O (90 : 10, v/v)] to give karaviloside VII (4, 10 mg, 0.0003%). Fraction 3-4 (7.2 g) was separated by reversed-phase silica gel column chromatography [200 g, MeOH–H₂O (70 : 30 \rightarrow 80 : 20 \rightarrow 90 : 10 \rightarrow 95 : 5, v/v) \rightarrow MeOH] to give five fractions [Fr. 3-4-1 (1.8 g), 3-4-2 (403 mg), 3-4-3 (128 mg), 3-4-4 (968 mg), 3-4-5 (3.7 g)]. Fraction 3-4-2 (403 mg) was purified by HPLC [1] MeOH-H₂O (80 : 20, v/v); 2] CH₃CN-H₂O (45 : 55, v/v)] to give karaviloside XI (8, 19 mg, 0.0006%). Fraction 3-4-3 (128 mg) was purified by HPLC [1] MeOH-H₂O (80 : 20, v/v); 2] CH₃CN-H₂O (45 : 55, v/v)] to give karaviloside VIII (5, 65 mg, 0.0020%). Fraction 7 (22.3 g) was separated by reversed-phase silica gel column chromatography [600 g, MeOH-H2O (70 : 30 \rightarrow 90 : 10, v/v) \rightarrow MeOH] to give four fractions [Fr. 7-1 (11.3 g), 7-2 (3.7 g), 7-3 (640 mg), 7-4 (4.6 g)]. Fraction 7-2 (3.7 g) was purified by normal-phase silica gel column chromatography [100 g, CHCl₃-MeOH-H₂O (15 : 3 : 1, lower layer, v/v) \rightarrow MeOH] to give seven fractions [Fr. 7-2-1 (320 mg), 7-2-2 (590 mg), 7-2-3 (603 mg), 7-2-4 (1.4 g), 7-2-5 (398 mg), 7-2-6 (937 mg), 7-2-7 (959 mg)]. Fraction 7-2-5 (398 mg) was purified by HPLC [MeOH-H₂O (70 : 30, v/v)] to give karaviloside X (7, 14 mg, 0.0006%). Fraction 7-2-6 (937 mg) was purified by HPLC [MeOH-H₂O (75 : 25, v/v)] to give karaviloside IX (6, 94 mg, 0.0042%).

Karavilagenin D (1): a white powder, $[\alpha]_{D}^{26}$ –94.4° (*c*=0.1, MeOH). High-resolution positive-ion FAB-MS: Calcd for C₃₀H₄₆O₄Na (M+Na)⁺: 493.3294. Found: 493.3388. IR (KBr): 3475, 1765 cm⁻¹. ¹H-NMR (pyridine-*d*₅, 500 MHz) δ : 0.86, 0.93, 0.95, 1.27 (3H each, all s, 29, 18, 28, 30-H₃), 0.89 (3H, d-like, 21-H₃), 1.31 (6H, s, 26, 27-H₃), 3.42 (1H, br s, 3-H), 5.60 (2H, m, 23, 24-H), 5.73 (1H, dd, *J*=3.3, 9.6 Hz, 7-H), 6.21 (1H, d, *J*=9.6 Hz, 6-H). ¹³C-NMR (125 MHz, pyridine-*d*₅) δ_{C} : given in Table 1. Positive-ion FAB-MS: *m/z* 493 (M+Na)⁺.

Karavilagenin E (**2**): a white powder, $[\alpha]_D^{26}$ –41.0° (*c*=0.1, MeOH). High-resolution positive-ion FAB-MS: Calcd for C₃₀H₄₉O₃ (M+H)⁺: 457.3682. Found: 457.3672. IR (KBr): 3475 cm⁻¹. ¹H-NMR (pyridine-*d*₅, 500 MHz) δ : 0.86, 1.20, 1.69, 1.71 (3H each, all s, 30, 28, 26, 27-H₃), 0.90 (6H, s, 18, 29-H₃), 0.98 (3H, d, *J*=6.3 Hz, 21-H₃), 3.41 (1H, dd-like, 3-H), 3.51, 3.67 (1H each, both d, *J*=8.6 Hz, 19-H₂), 4.46 (1H, ddd, *J*=3.0, 8.3, 11.8 Hz, 23-H), 5.20 (1H, d, *J*=8.3 Hz, 24-H), 5.64 (1H, dd, *J*=3.6, 9.9 Hz, 7-H), 6.04 (1H, d, *J*=9.9 Hz, 6-H). ¹³C-NMR (125 MHz, pyridine-*d*₅) δ_C : given in Table 1. Positive-ion FAB-MS: *m/z* 457 (M+H)⁺.

Karaviloside VI (**3**): a white powder, $[\alpha]_D^{28}$ –80.0° (*c*=0.1, MeOH). High-resolution positive-ion FAB-MS: Calcd for C₃₇H₅₈O₉Na (M+Na)⁺: 669.3979. Found: 669.3992. IR (KBr): 3432, 1750, 1078, 1040 cm⁻¹. ¹H-NMR (pyridine-*d*₅, 500 MHz) & 0.83, 0.89, 0.94, 1.58 (3H each, all s, 30, 18, 29, 28-H₃), 0.95 (3H, dlike, 21-H₃), 1.33 (6H, s, 26, 27-H₃), 3.22 (3H, s, 25-OMe), 3.67 (1H, br s, 3-H), 4.83 (1H, d, *J*=7.9 Hz, 1'-H), 5.57 (1H, d, *J*=15.9 Hz, 24-H), 5.65 (2H, m, 6, 23-H), 6.33 (1H, dd, *J*=2.1, 9.5 Hz, 7-H). ¹³C-NMR (125 MHz, pyridine-*d*₅) δ_C : given in Table 1. Negative-ion FAB-MS: *m/z* 645 (M–H)⁻. Positive-ion FAB-MS: *m/z* 669 (M+Na)⁺, 691 (M+2Na–H)⁺.

Karaviloside VII (**4**): a white powder, $[\alpha]_D{}^{27}$ –36.3° (*c*=0.1, MeOH). High-resolution positive-ion FAB-MS: Calcd for C₃₇H₆₁O₈ (M+H)⁺: 633.4366. Found: 633.4361. IR (KBr): 3453, 1084, 1034 cm⁻¹. ¹H-NMR (500 MHz, pyridine-*d*₅) δ : 0.90, 0.80, 0.93, 1.52, 1.71, 1.75 (3H each, all s, 30, 18, 29, 28, 26, 27-H₃), 1.06 (3H, d, *J*=6.4 Hz, 21-H₃), 3.30 (3H, s, 23-OMe), 3.59, 3.73 (1H each, both d, *J*=8.0 Hz, 19-H₂), 3.69 (1H, br s, 3-H), 3.96 (1H, m, 23-H), 4.90 (1H, d, *J*=7.6 Hz, 1'-H), 5.23 (1H, d-like, 24-H), 5.57 (1H, dd, *J*=4.0, 9.8 Hz, 7-H), 6.21 (1H, d-like, 6-H). ¹³C-NMR (125 MHz, pyridine-*d*₅) δ_C : given in Table 1. Negative-ion FAB-MS: *m/z* 631 (M–H)⁻. Positive-ion FAB-MS: *m/z* 633 (M+H)⁺.

Karaviloside VIII (**5**): a white powder, $[\alpha]_D^{28}$ –47.4° (*c*=0.1, MeOH). High-resolution positive-ion FAB-MS: Calcd for C₃₆H₅₉O₉ (M+H)⁺: 635.4159. Found: 635.4155. IR (KBr): 3520, 1084, 1034 cm⁻¹. ¹H-NMR (500 MHz, pyridine-*d*₅) δ : 0.77, 0.87, 0.89, 1.35, 1.64, 1.85 (3H each, all s, 18, 30, 29, 28, 26, 27-H₃), 1.16 (3H, d, *J*=6.9 Hz, 21-H₃), 3.51 (1H, br s, 3-H), 3.55, 3.74 (1H each, both d, *J*=8.3 Hz, 19-H₂), 4.02 (1H, dd, *J*=2.2, 7.9 Hz, 22-H), 4.64 (1H, t-like, 23-H), 5.51 (1H, m, 24-H), 5.53 (1H, d, *J*=7.9 Hz, 1'-H), 5.62 (1H, dd, *J*=3.6, 9.9 Hz, 7-H), 6.14 (1H, d, *J*=9.9 Hz, 6-H). ¹³C-NMR (125 MHz, pyridine-*d*₅) δ_C : given in Table 1. Negative-ion FAB-MS: *m/z* 633 (M–H)⁻. Positive-ion FAB-MS: *m/z* 635 (M+H)⁺, 657 (M+Na)⁺.

Karaviloside IX (6): a white powder, $[\alpha]_D^{26}$ –96.6° (*c*=0.1, MeOH). High-resolution positive-ion FAB-MS: Calcd for C₄₂H₆₉O₁₄ (M+H)⁺: 797.4688. Found: 797.4681. IR (KBr): 3453, 1082, 1036 cm⁻¹. ¹H-NMR (500 MHz, pyridine-*d*₅) δ : 0.74, 0.88, 0.91, 1.48, 1.63, 1.83 (3H each, all s, 18, 30, 29, 28, 26, 27-H₃), 1.14 (3H, d, *J*=6.9 Hz, 21-H₃), 3.58, 3.73 (1H each, both d, *J*=7.9 Hz, 19-H₂), 3.65 (1H, br s, 3-H), 4.01 (1H, dd-like, 22-H), 4.68 (1H, t-like, 23-H), 4.84 (1H, d, *J*=7.6 Hz, 1'-H), 5.54 (1H, d, *J*=7.9 Hz, 1"-H), 5.54 (2H, m, 7, 24-H), 6.19 (1H, d, J=9.6 Hz, 6-H). ¹³C-NMR (125 MHz, pyridine- d_5) δc : given in Table 1. Negative-ion FAB-MS: m/z 795 (M–H)⁻. Positive-ion FAB-MS: m/z 797 (M+H)⁺, 819 (M+Na)⁺.

Karaviloside X (7): a white powder, $[\alpha]_D{}^{28}$ –80.7° (*c*=0.1, MeOH). High-resolution positive-ion FAB-MS: Calcd for C₄₂H₆₉O₁₄ (M+H)⁺: 797.4687. Found: 797.4694. IR (KBr): 3432, 1084, 1034 cm⁻¹. ¹H-NMR (500 MHz, pyridine-*d*₅) δ : 0.75, 1.45, 1.63, 1.85 (3H each, all s, 18, 28, 26, 27-H₃), 0.89 (6H, s, 29, 30-H₃), 1.15 (3H, d, *J*=7.0 Hz, 21-H₃), 3.59, 3.76 (1H each, both d, *J*=8.3 Hz, 19-H₂), 3.62 (1H, br s, 3-H), 4.01 (1H, dd-like, 22-H), 4.63 (1H, t-like, 23-H), 5.34 (1H, d, *J*=7.9 Hz, 1'-H), 5.52 (1H, d, *J*=10.2 Hz, 24-H), 5.56 (1H, d, *J*=7.9 Hz, 1"-H), 5.77 (1H, dd, *J*=3.6, 9.8 Hz, 7-H), 6.18 (1H, d, *J*=9.8 Hz, 6-H). ¹³C-NMR (125 MHz, pyridine-*d*₅) δ_C : given in Table 1. Negative-ion FAB-MS: *m/z* 795 (M-H)⁻, 633 (M-C₆H₁₁O₅)⁻. Positive-ion FAB-MS: *m/z* 797 (M+H)⁺, 819 (M+Na)⁺.

Karaviloside XI (8): a white powder, $[\alpha]_D^{27}$ –49.5° (*c*=0.1, MeOH). High-resolution positive-ion FAB-MS: Calcd for C₃₆H₆₁O₁₀ (M+H)⁺: 653.4265. Found: 653.4267. IR (KBr): 3432, 1084, 1032 cm⁻¹. ¹H-NMR (pyridine-*d*₅, 500 MHz) δ : 0.79, 0.88, 0.89, 1.46, 1.61, 1.63 (3H, s, 18, 30, 29, 28, 26, 27-H₃), 1.12 (3H, d, *J*=6.4 Hz, 21-H₃), 3.58, 3.76 (1H each, both d, *J*=7.9 Hz, 19-H₂), 3.52 (1H, d-like, 24-H), 3.65 (1H, br s, 3-H), 4.53 (1H, ddd-like, 23-H), 5.37 (1H, d, *J*=7.9 Hz, 1'-H), 5.55 (1H, dd, *J*=3.9, 9.5 Hz, 7-H), 6.18 (1H, d, *J*=9.5 Hz, 6-H). ¹³C-NMR (125 MHz, pyridine-*d*₅) δ_C : given in Table 1. Negative-ion FAB-MS: *m/z* 651 (M–H)⁻. Positive-ion FAB-MS: *m/z* 653 (M+H)⁺, 675 (M+Na)⁺.

Acid Hydrolysis of Karavilosides (4–8): A solution of 4–8 (3 mg each) in 5% aqueous H₂SO₄–1,4dioxane was heated under reflux for 1 h. After cooling, the reaction mixture was neutralized with Amberlite IRA-400 (OH⁻ form) and residue was removed by filtration. After removal of the solvent from the filtrate *in vacuo*, the residue was transferred to a Sep-Pak C18 cartridge with H₂O and MeOH. The H₂O eluate was concentrated and the residue was treated with L–cysteine methyl ester hydrochloride (4 mg) in pyridine (0.5 ml) at 60 °C for 1 h. After reaction, the solution was treated with *N*,*O*bis(trimethylsilyl)trifluoroacetamide (0.2 ml) at 60 °C for 1 h. The supernatant was then subjected to GLC analysis to identify the derivatives of D-glucose (i) from **3**, **4** and **6**; D-allose (ii) from **5**, **6**, **7** and **8**; GLC conditions: column, Supeluco STBTM-1, 30 m x 0.25 mm (i.d.) capillary column; column temperature, 230 °C; carrier gas, N₂; $t_{\rm R}$, (i) 17.7 min (ii) 23.2 min (iii) 24.1 min (L-allose).

MeOH Treatment of karavilagenin C: A solution of karavilagenin C (5.0 mg, 0.01 mmol) in MeOH (2 mL) was refluxed for 48 hr. After cooling, the mixture was evaporated to dryness under reduced pressure and the residue was purified by reversed-phase silica gel column chromatography [1.0 g, CHCl₃–MeOH (30 : 1, v/v)] to give karavilagenin A (1 mg, 19%). The obtained compound, karavilagenin A, was identified by comparison of EI-MS and ¹H-NMR data of isolated compound, karavilagenin A.

ACKNOWLEDGMENTS

This research was supported by the 21st COE program, Academic Frontier Project, and Grand-in Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

REFERENCES AND NOTES

- 1 E. H. Karunanayake, J. Welihinda, S. R. Sirimanne, and G. Sinnadarai, *J. Ethnopharmacol.*, 1984, **11**, 223.
- 2 H. Okabe, Y. Miyahara, T. Yamauchi, K. Miyahara, and T. Kawasaki, *Chem. Pharm. Bull.*, 1980, **28**, 2753.
- 3 Y. Miyahara, H. Okabe, and T. Yamauchi, *Chem. Pharm. Bull.*, 1981, 29, 1561.
- 4 H. Okabe, Y. Miyahara, and T. Yamauchi, *Chem. Pharm. Bull.*, 1982, **30**, 3977.
- 5 H. Okabe, Y. Miyahara, and T. Yamauchi *Chem. Pharm. Bull.*, 1982, **30**, 4334.
- 6 M. Yasuda, M. Iwamoto, H. Okabe, and T. Yamauchi, *Chem. Pharm. Bull.*, 1984, **32**, 2044.
- 7 M. O. Fatope, Y. Takeda, H. Yamashita, H. Okabe, and T. Yamauchi, J. Nat. Prod., 1990, 53, 1491.
- 8 Y. Kimura, T. Akihisa, N. Yuasa, M. Ukiya, T. Suzuki, M. Toriyama, S. Motohashi, and H. Tokuda, *J. Nat. Prod.*, 2005, **68**, 807.
- 9 C.-I. Chang, C.-R. Chen, Y.-W. Liao, H.-L. Cheng, Y.-C. Chen, and C.-H. Chou, J. Nat. Prod., 2006, 69, 1168.
- 10 T. Murakami, A. Emoto, H. Matsuda, and M. Yoshikawa, Chem. Pharm. Bull., 2001, 49, 54.
- 11 S. Nakamura, T. Murakami, J. Nakamura, H. Kobayashi, H. Matsuda, and M. Yoshikawa, *Chem. Pharm. Bull.*, 2006, **54**, 1545.
- 12 The ¹H- and ¹³C-NMR spectra of for **1–8** were assigned with the aid of homo- and hetero- correlation spectroscopy (¹H-¹H, ¹H-¹³C COSY), distortionless enhancement by polarization transfer (DEPT), and heteonuclear multiple bond correlation (HMBC) experiments.
- 13 S. Hara, H. Okabe, and K. Mihashi, *Chem. Pharm. Bull.*, 1986, **34**, 1843.